From the left: D A Prasanna, Founder and Chairman of the Board of Ecron Acunova, Ingelise Saunders, Chairman of Ecron Acunova A/S, R K Arora, Head of Chancery at the Embassy of India Søren Strøh, CEO of Ecron Acunova A/S and Birgitte Guldhammer, Managing Director of Ecron Acunova A/S
The reception was held at Ecron Acunova’s Nordic Headquarters based in Denmark’s leading bio-science park, SCION DTU in Hoersholm near Copenhagen and organized together with Invest in Denmark from the Danish Ministry of Foreign Affairs.
At the event, Mr. Prasanna, Chairman and Founder of Ecron Acunova, explained that speed to market is one of the strategic reason for the new Danish presence: “Several examples of innovation in GE Medical and Wipro have inspired me to apply similar principles to accelerate speed to market in clinical research. In clinical trials a basic factor is fast enrolment of patients. Through an intelligent combination of countries and competencies, we can speed new drugs to market at a modest cost.”
The combined track record of the two companies and network in their respective regions will strengthen Ecron Acunova in the global competition. For the same reason, Ecron Acunova sees a growth synergy rather than a cost synergy in the merger. Currently, the company has 35 employees in Denmark, and the intention is to grow significantly within the near future.
Mr. Søren Strøh, Founder of aCROnordic, continues his role as CEO in the Nordic region:“As an international company, Ecron Acunova A/S will be able to attract international clinical trial projects offering access to Danish sites and highly qualified clinical research experience and skills. We are able to conduct and monitor clinical trials offering a flexible cost effective high quality approach without potential cultural barriers.”
Competitive Danish R&D
A contract research organization (CRO) is a service organization that provides support to the pharmaceutical and biotechnology industries in the form of outsourced pharmaceutical research services for both drugs and medical devices. Denmark possesses a strong life science cluster and is particularly skilled when it comes to research and development.
Invest in Denmark has helped Ecron Acunova establish in Denmark and appreciates the increasing Indian interest in Danish life science. Director of Invest in Denmark at the Ministry of Foreign Affairs, Ole Frijs-Madsen, explains:”Denmark has unique life science competences, especially within research and development, and we further strengthen this business area by welcoming a global player as Ecron Acunova.”
Please contact Invest in Denmark’s life science experts Tine Hartmann Nielsen at email@example.com or Pramila Das firstname.lastname@example.org to learn more about this specific case or the Danish life science sector in general.